Quick Nav
Publications
Pharmacy Times
Rx Focus

New Guidelines for the Management of Patients with MI

Jennifer A. Ng, PharmD; Bao Q. Nguyen, PharmD; and Mohammad J. Tafreshi, PharmD, BCPS
Published Online: Monday, November 1, 2004   [ Request Print ]

Statistics indicate that in 2001 there were ~1.7 million hospital discharges for acute coronary syndromes (ACS). According to the National Registry of Myocardial Infarction 4, it is estimated that ~30% of the ACS patients have ST-elevation myocardial infarction (STEMI). This percentage translates to ~500,000 STEMI events per year in the United States.1,2

New Guidelines

Recently, the American Heart Association (AHA), in partnership with the American College of Cardiology (ACC), published a new set of guidelines for the management of patients with STEMI.3 The focus of this article is on medications used in the management of STEMI patients.

For ease of comparison, a Table is provided that reviews and compares only the changes between the old (1999) and the new (2004) guidelines. Readers are encouraged to refer to the actual guidelines for a comprehensive review of each section.

Recommendation Classifications and Levels of Evidence

The customary ACC/AHA classifications (I, 7 IIa, IIb, and III) and levels of evidence (A, B, and C) are used in these guidelines:

  • Class I: Conditions for which there is evidence or general agreement that a given procedure or treatment is useful and effective
  • Class II: Conditions for which there is conflicting evidence or a divergence of opinion about the usefulness/efficacy of a procedure or treatment
  • Class IIa: Weight of evidence/opinion in favor of usefulness/ efficacy
  • Class IIb: Usefulness/efficacy less well established by evidence/opinion
  • Class III: Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful
  • Level of Evidence A: Data derived from multiple population risk strata
  • Level of Evidence B: Data derived from limited population risk strata
  • Level of Evidence C: Data derived from very limited risk strata

Figure

Figure

Figure

For a list of references, send a stamped, self-addressed envelope to: References Department, Attn. A. Stahl, Pharmacy Times, 241 Forsgate Drive, Jamesburg, NJ 08831; or send an e-mail request to: astahl@mwc.com.

Dr. Ng is an instructor of pharmacy practice and a cardiology pharmacy practice resident, Midwestern University, College of Pharmacy-Glendale. Dr. Nguyen is a pharmacist with Banner Thunderbird Medical Center. Dr. Tafreshi is an associate professor of pharmacy and medicine and director of the cardiology pharmacy practice residency, Midwestern University, College of Pharmacy-Glendale.

Related Articles
No Result Found




Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-257-0701

Copyright HCPLive 2006-2013
Intellisphere, LLC. All Rights Reserved.
 




Become a Member
Forgot Password?